EP2780082A4 - Compositions et méthodes de traitement de la maladie d'alzheimer - Google Patents

Compositions et méthodes de traitement de la maladie d'alzheimer

Info

Publication number
EP2780082A4
EP2780082A4 EP12847618.1A EP12847618A EP2780082A4 EP 2780082 A4 EP2780082 A4 EP 2780082A4 EP 12847618 A EP12847618 A EP 12847618A EP 2780082 A4 EP2780082 A4 EP 2780082A4
Authority
EP
European Patent Office
Prior art keywords
disease
compositions
methods
treating alzheimer
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12847618.1A
Other languages
German (de)
English (en)
Other versions
EP2780082A1 (fr
Inventor
Neil R Cashman
Grant Mcclarty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
CNJ Holdings Inc
Original Assignee
University of British Columbia
Cangene US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Cangene US Inc filed Critical University of British Columbia
Publication of EP2780082A1 publication Critical patent/EP2780082A1/fr
Publication of EP2780082A4 publication Critical patent/EP2780082A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP12847618.1A 2011-11-10 2012-11-12 Compositions et méthodes de traitement de la maladie d'alzheimer Withdrawn EP2780082A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161558430P 2011-11-10 2011-11-10
US201261589809P 2012-01-23 2012-01-23
US201213582308A 2012-08-31 2012-08-31
PCT/US2012/064722 WO2013071267A1 (fr) 2011-11-10 2012-11-12 Compositions et méthodes de traitement de la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
EP2780082A1 EP2780082A1 (fr) 2014-09-24
EP2780082A4 true EP2780082A4 (fr) 2015-08-05

Family

ID=48290671

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12847618.1A Withdrawn EP2780082A4 (fr) 2011-11-10 2012-11-12 Compositions et méthodes de traitement de la maladie d'alzheimer

Country Status (8)

Country Link
EP (1) EP2780082A4 (fr)
CN (1) CN104093454A (fr)
AU (1) AU2012335014A1 (fr)
CA (1) CA2855669A1 (fr)
EA (1) EA201491851A1 (fr)
HK (1) HK1201771A1 (fr)
SG (1) SG11201403272YA (fr)
WO (1) WO2013071267A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2644335C2 (ru) 2010-03-03 2018-02-08 Зе Юниверсити Оф Бритиш Коламбия Эпитоп, специфичный к олигомеру амилоида бета, и антитела
EP3102611A4 (fr) * 2014-02-03 2017-08-23 Cangene Corporation Molécules de liaison à des bêta-amyloïdes humanisées et utilisations de celles-ci
WO2016008047A1 (fr) * 2014-07-14 2016-01-21 Cangene Corporation Vaccination peptidique cyclique pour le traitement de troubles liés à la protéine bêta-amyloïde
WO2016187339A1 (fr) * 2015-05-18 2016-11-24 Synaptec Development Llc Clairance de galantamine d'amyloides
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
EP3374380A4 (fr) * 2015-11-09 2019-05-15 The University Of British Columbia Épitopes en c-terminal dans la bêta-amyloïde et anticorps conformationnels sélectifs associés
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CA3004496A1 (fr) * 2015-11-09 2017-05-18 Neil R. Cashman Epitopes dans la beta-amyloide et anticorps conformationnels selectifs associes
CA3004494A1 (fr) * 2015-11-09 2017-05-18 The University Of British Columiba Epitopes dans la region centrale de la beta-amyloide et anticorps conformationnels selectifs associes
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CN112661828B (zh) * 2021-01-15 2022-04-01 武汉大学 一种突触素的抗原肽及其抗体与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010002251A1 (fr) * 2008-07-01 2010-01-07 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccin contre un intermédiaire de repliement des amyloïdes
WO2011106885A1 (fr) * 2010-03-03 2011-09-09 The University Of British Columbia Epitope d'amyloïde bêta spécifique de l'oligomère et anticorps
WO2016008047A1 (fr) * 2014-07-14 2016-01-21 Cangene Corporation Vaccination peptidique cyclique pour le traitement de troubles liés à la protéine bêta-amyloïde

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110306605A1 (en) * 2008-12-22 2011-12-15 Sloan-Kettering Institute For Cancer Research Coumarin-based compounds for the treatment of alzheimer's disease and cancer
KR20130043088A (ko) * 2010-02-09 2013-04-29 브리스톨-마이어스 스큅 컴퍼니 면역검정 표준물 및 검정내 보정 표준물을 사용한 임상 바이오마커의 측정

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010002251A1 (fr) * 2008-07-01 2010-01-07 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccin contre un intermédiaire de repliement des amyloïdes
WO2011106885A1 (fr) * 2010-03-03 2011-09-09 The University Of British Columbia Epitope d'amyloïde bêta spécifique de l'oligomère et anticorps
WO2016008047A1 (fr) * 2014-07-14 2016-01-21 Cangene Corporation Vaccination peptidique cyclique pour le traitement de troubles liés à la protéine bêta-amyloïde

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRIAN O'NUALLAIN ET AL: "Human Plasma Contains Cross-Reactive A[beta] Conformer-Specific IgG Antibodies +", BIOCHEMISTRY, vol. 47, no. 47, 25 November 2008 (2008-11-25), pages 12254 - 12256, XP055198127, ISSN: 0006-2960, DOI: 10.1021/bi801767k *
MAGGA JOHANNA ET AL: "Human intravenous immunoglobulin provides protection against AÎ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease", JOURNAL OF NEUROINFLAMMATION, BIOMED CENTRAL LTD., LONDON, GB, vol. 7, no. 1, 7 December 2010 (2010-12-07), pages 90, XP021089590, ISSN: 1742-2094, DOI: 10.1186/1742-2094-7-90 *
MICHELA ROSINI ET AL: "Inhibition of Acetylcholinesterase, [beta]-Amyloid Aggregation, and NMDA Receptors in Alzheimer's Disease: A Promising Direction for the Multi-target-Directed Ligands Gold Rush", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 15, 1 August 2008 (2008-08-01), pages 4381 - 4384, XP055198095, ISSN: 0022-2623, DOI: 10.1021/jm800577j *
See also references of WO2013071267A1 *

Also Published As

Publication number Publication date
CA2855669A1 (fr) 2013-05-16
SG11201403272YA (en) 2014-08-28
EP2780082A1 (fr) 2014-09-24
WO2013071267A1 (fr) 2013-05-16
CN104093454A (zh) 2014-10-08
AU2012335014A1 (en) 2014-06-19
HK1201771A1 (en) 2015-09-11
EA201491851A1 (ru) 2015-12-30

Similar Documents

Publication Publication Date Title
EP2780082A4 (fr) Compositions et méthodes de traitement de la maladie d'alzheimer
EP2819687A4 (fr) Compositions et méthodes de traitement d'une maladie vasculaire périphérique
EP2550263A4 (fr) Compositions et méthodes de traitement d'une maladie neurodégénérative
EP2699256A4 (fr) Compositions et méthodes de traitement de maladie de devic
EP2542255A4 (fr) Méthodes et compositions pour le traitement de la maladie de degos
EP2854852A4 (fr) Compositions et procédés de traitement de la maladie de crohn et des pathologies et infections associées
EP2707369A4 (fr) Compositions et procédés pour traiter la maladie d'alzheimer
EP2892546A4 (fr) Compositions et méthodes de traitement d'une cicatrice cutanée
EP2820159A4 (fr) Procédés et compositions permettant de traiter la maladie de huntington
EP2608778A4 (fr) Compositions et méthodes de traitement d'anomalies osseuses
EP2854839A4 (fr) Méthodes de traitement de la maladie c liaque
EP2766390A4 (fr) Compositions et méthodes de traitement d'une insuffisance cardiaque
EP2635282A4 (fr) Compositions et méthodes de traitement de la myélofibrose
IL237369A0 (en) Methods for treating Alzheimer's disease and pharmaceutical compositions thereof
EP2585075A4 (fr) Méthodes de traitement de l'inflammation sophagienne
EP3019523A4 (fr) Méthodes permettant de traiter la maladie d'alzheimer et la maladie de huntington
EP2795325A4 (fr) Méthodes de diagnostic de la maladie d'alzheimer
EP2729148A4 (fr) Compositions et méthodes de traitement de symptômes chez des patients atteints de la maladie de parkinson
EP2723898A4 (fr) Méthodes et compositions pour traitement et diagnostique d'un cancer de la vessie
EP2863941A4 (fr) Composition et méthode de traitement de la maladie de gaucher de type iii
EP2866894A4 (fr) Compositions et procédés de traitement de la maladie d'alzheimer
EP2704723A4 (fr) Traitement d'une maladie polykystique
EP2786738A4 (fr) Composition d'agent de traitement des cheveux
EP2695154A4 (fr) Traitement d'orthophonie assisté par ordinateur
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150703

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20150629BHEP

Ipc: C07K 16/06 20060101AFI20150629BHEP

Ipc: C07K 14/47 20060101ALI20150629BHEP

Ipc: A61K 39/395 20060101ALI20150629BHEP

Ipc: C07K 7/64 20060101ALI20150629BHEP

Ipc: A61P 25/28 20060101ALI20150629BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201771

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MCCLARTY, GRANT

Owner name: CANGENE U.S. INCORPORATED

Owner name: THE UNIVERSITY OF BRITISH COLUMBIA

Owner name: CASHMAN, NEIL R.

Owner name: CANGENE CORPORATION

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CNJ HOLDINGS INC.

Owner name: THE UNIVERSITY OF BRITISH COLUMBIA

17Q First examination report despatched

Effective date: 20170811

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171222

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1201771

Country of ref document: HK